康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06185 康希诺生物

未开盘 04-24 16:08:16

18.060

-0.340

-1.85%

最高18.800	最低17.940	成交量78.38万
今开18.800	昨收18.400	日振幅4.67%
总市值44.69亿	流通市值23.96亿	总股本2.47亿
成交额1,419万	换手率0.59%	流通股本1.33亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":18.06,"timestamp":1713946096019,"preClose":18.4,"halted":0,"volume":783800,"delay":0,"floatShares":132670900,"shares":247449899,"eps":-6.470697,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.34,"latestTime":"04-24 16:08:16","open":18.8,"high":18.8,"low":17.94,"amount":14193768,"amplitude":0.046739,"askPrice":18.1,"askSize":6200,"bidPrice":18.06,"bidSize":600,"shortable":3,"etf":0,"ttmEps":-6.470696700129989,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714008600000},"adr":0,"listingDate":1553702400000,"adjPreClose":18.4,"dividendRate":0.050004,"openAndCloseTimeList":[[1713922200000,1713931200000],[1713934800000,1713945600000]],"volumeRatio":0.5715910914508373,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":47.86,"timestamp":1713942000000,"preClose":48.45,"halted":0,"volume":1183115,"delay":0,"premium":"-64.95"}},"requestUrl":"/m/hq/s/06185/tweets","defaultTab":"tweets","newsList":[{"id":"2429486036","title":"智通AH统计|4月24日","url":"https://stock-news.laohu8.com/highlight/detail?id=2429486036","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429486036?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:15","pubTimestamp":1713946505,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止4月24日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为1105.36%、762.40%、628.14%；招商银行、比亚迪股份、紫金矿业分列AH溢价率末三位，溢价率分别为21.27%、23.48%、23.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108407.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429506891","title":"康希诺生物上榜04月23日主力资金加仓幅度前10个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2429506891","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429506891?lang=zh_cn&edition=full","pubTime":"2024-04-23 16:16","pubTimestamp":1713860208,"startTime":"0","endTime":"0","summary":"04月23日, 康希诺生物股价涨5.14%，报收18.40元，成交金额4268万元，换手率1.76%，振幅6.06%，量比2.17。康希诺生物今日主力资金净流入1126万元，上一交易日主力净流入115万元，今日环比增加879.13%。该股近5个交易日上涨6.98%，主力资金累计净流入1027万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1367万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231617438b49b211&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231617438b49b211&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429153834","title":"港股异动 | 医药股午后拉升走强 创新药政策向好态势明显 二季度后板块有望持续转暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2429153834","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429153834?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:55","pubTimestamp":1713851752,"startTime":"0","endTime":"0","summary":"消息面上，近日，北京市医保局印发《北京市支持创新医药高质量发展若干措施》。东海证券近日研报指出，今年以来包括对创新药的明确支持、集采续约条款的持续优化等，行业政策向好态势明显；二季度以后板块整体有望持续转暖向好。中长期来看，持续看好创新药、特色器械等代表新质生产力发展方向的投资机会；中短期来看，重点关注品牌中药、连锁药店、血制品等低估值、高股息，成长稳健的相关板块及个股的投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107395.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027158","title":"生物医药板块午后发力 药明合联(02268)涨8.59% 机构指行业今年依然有结构性增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027158","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429027158?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:53","pubTimestamp":1713851628,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块午后发力走高，药明合联 涨8.59%，荣昌生物涨6.53%，信达生物涨6.48%，康希诺生物涨6.4%，维亚生物涨5.88%，和黄医药涨5.58%，康方生物涨5.41%。华鑫证券表示，2024年1季度行业增长受到同期基数影响较为明显，如零售药店、POCT等，展望2024年全年，1季度高增长方向具有代表性，其增长趋势有望延续，医药行业依然有结构性增量。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935593","is_publish_highlight":false,"gpt_icon":0},{"id":"2429307971","title":"康希诺生物(06185): Hib疫苗获批准开展临床试验，重组肺炎球菌蛋白疫苗I期试验见成效","url":"https://stock-news.laohu8.com/highlight/detail?id=2429307971","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429307971?lang=zh_cn&edition=full","pubTime":"2024-04-23 13:10","pubTimestamp":1713849045,"startTime":"0","endTime":"0","summary":"快讯正文康希诺生物股价今日大涨，最高涨幅接近6%。截至发稿时，公司股价攀升4.69%，报收于18.32港元，成交额达到830.79万港元。根据公司公告，康希诺生物研发的冻干b型流感嗜血杆菌结合疫苗已成功获得国家药监局的批准，即将展开相关临床试验。此外，该公司近期还公布了其研发的重组肺炎球菌蛋白疫苗在I期临床试验中取得的积极初步结果。基于I期临床试验的初步成果，康希诺生物计划进行下一阶段的PBPV研发工作评估与规划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042313424387a467ba&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429133401","title":"生物疫苗概念盘中跳水，康希诺跌0.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429133401","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429133401?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:47","pubTimestamp":1713840430,"startTime":"0","endTime":"0","summary":"04月23日，生物疫苗概念盘中跳水，截至10点47分，生物疫苗概念整体指数下跌1.02%，报1839.910点。从个股上来看，该概念的成分股中，康希诺跌0.02%，跌幅居前。从资金上来看，截止发稿，生物疫苗概念主力净流入为-2.10亿，其中神州细胞-U受到资金热捧，主力净流入2184.36万；拉长时间线来看，该板块近20日主力资金净流入-28.01亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423104710861e80bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240423104710861e80bf&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429138225","title":"康希诺生物现涨近4% 冻干b型流感嗜血杆菌结合疫苗药物临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2429138225","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429138225?lang=zh_cn&edition=full","pubTime":"2024-04-23 10:23","pubTimestamp":1713838984,"startTime":"0","endTime":"0","summary":"康希诺生物（06185）早盘曾一度涨近6%，高见18.54港元，涨幅现收窄至上涨3.89%，报18.18港元，成交额991.15万港元。\n　　康希诺生物发布公告称，公司研发的冻干b型流感嗜血杆菌（Hib）结合疫苗（Hib疫苗）已获得国家药监局批准，可以开展相关临床试验。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuqpz0183745.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-04-23/doc-inasuqpz0183745.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429187135","title":"港股异动 | 康希诺生物(06185)一度涨近6% 冻干b型流感嗜血杆菌结合疫苗药物临床试验获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2429187135","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429187135?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:53","pubTimestamp":1713837205,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物(06185)一度涨近6%，截至发稿，涨4.69%，报18.32港元，成交额830.79万港元。消息面上，康希诺生物发布公告称，公司研发的冻干b型流感嗜血杆菌(Hib)结合疫苗(Hib疫苗)已获得国家药监局批准，可以开展相关临床试验。此外，公司近期公布，其研发的重组肺炎球菌蛋白疫苗于I期(包括Ia 期及Ib期)临床试验中获得了积极的初步结果。公司将基于I期临床试验中获得的初步结果，进行下一阶段PBPV研发工作的评估和规划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107320.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429182090","title":"南向资金4月22日净买入康希诺生物13.26万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2429182090","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429182090?lang=zh_cn&edition=full","pubTime":"2024-04-23 09:31","pubTimestamp":1713835874,"startTime":"0","endTime":"0","summary":"4月22日, 南向资金增持康希诺生物13.26万股，连续7日增持。截止当日收盘，港股通共持有康希诺生物4765.32万股，占流通股35.91%。港股通增持金额前五个股分别为腾讯控股、中国银行、建设银行、中国石油化工股份、中通快递-W。康希诺生物近5个交易日上涨0.57%，港股通累计增持64.88万股；近20个交易日上涨3.43%，港股通累计增持87.48万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309474087a38938&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042309474087a38938&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429764459","title":"康希诺生物(06185.HK)流感嗜血杆菌结合疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429764459","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429764459?lang=zh_cn&edition=full","pubTime":"2024-04-23 00:23","pubTimestamp":1713802980,"startTime":"0","endTime":"0","summary":"康希诺生物(06185.HK) 公布，公司研发的冻干b型流感嗜血杆菌(Hib)结合疫苗(Hib疫苗)已获中国国家药品监督管理局批准，可以开展相关临床试验。流感嗜血杆菌为革兰阴性杆菌，是儿童急性下呼吸道感染最主要的病原菌之一。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-22 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20210709173208325_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20210709173208325_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1344054/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2429415129","title":"康希诺生物(06185)：冻干b型流感嗜血杆菌结合疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2429415129","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429415129?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:57","pubTimestamp":1713783462,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司研发的冻干b型流感嗜血杆菌结合疫苗已获得中华人民共和国国家药品监督管理局批准，可以开展相关临床试验。流感嗜血杆菌为革兰阴性杆菌，是儿童急性下呼吸道感染最主要的病原菌之一，分为有荚膜型和无夹膜型，两者均可引发感染。有荚膜的菌株根据荚膜多糖的化学成分来进行分类，迄今已发现6种血清型，其中，约95%的侵袭性流感嗜血杆菌疾病由b型引起。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106717.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429917671","title":"康希诺董秘回复： 基于四价流脑结合疫苗的高端市场定位，销售和市场拓展方面","url":"https://stock-news.laohu8.com/highlight/detail?id=2429917671","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429917671?lang=zh_cn&edition=full","pubTime":"2024-04-22 17:01","pubTimestamp":1713776509,"startTime":"0","endTime":"0","summary":"证券之星消息，康希诺04月22日在投资者关系平台上答复投资者关心的问题。在三四五线城市的下沉商业化中，公司如何考量成本和销量的关系？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221701558b457b34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221701558b457b34&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429996911","title":"智通AH统计|4月22日","url":"https://stock-news.laohu8.com/highlight/detail?id=2429996911","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429996911?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:15","pubTimestamp":1713773706,"startTime":"0","endTime":"0","summary":"智通财经APP数据显示，截止4月22日收盘，东北电气、弘业期货、浙江世宝分列AH溢价率前三位，溢价率分别为1185.71%、754.10%、608.76%；招商银行、比亚迪股份、潍柴动力分列AH溢价率末三位，溢价率分别为23.62%、24.41%、29.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106450.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429391069","title":"康希诺生物(6185.HK)：重组肺炎球菌蛋白疫苗I期临床试验取得积极成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2429391069","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429391069?lang=zh_cn&edition=full","pubTime":"2024-04-22 15:30","pubTimestamp":1713771045,"startTime":"0","endTime":"0","summary":"快讯正文【康希诺生物股价尾盘大涨逾7%】康希诺生物在4月22日尾盘的交易中股价大幅上涨，涨幅超过了7%，收盘价格达到了17.64港元，公司的总市值随之攀升至43.6亿港元。究其原因，该公司公开表示，其研发的重组肺炎球菌蛋白疫苗(PBPV)在I期临床试验中取得了积极的初步结果。这一结果暗示，PBPV在成年人以及老年人群中的安全性表现优异，未发现任何3级不良反应，也未观测到特殊的安全性风险。康希诺生物计划利用I期临床试验获得的这些初步结果，对PBPV的下一阶段研发工作进行评估和规划。下载和讯APP查看快讯，体验更佳>>","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221715198b4589c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221715198b4589c1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429993399","title":"【AH互动】康希诺(06185)AH股齐升逾4% 重组肺炎球菌蛋白疫苗I期临床试验取得积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2429993399","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2429993399?lang=zh_cn&edition=full","pubTime":"2024-04-22 11:26","pubTimestamp":1713756412,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康希诺生物(06185)早盘反复扬升，截至发稿，报17.32港元，涨4.97%，成交额1207.69万港元。另外，对应A股康希诺(688185)同步走高，暂报47.51元人民币，涨4.51%，成交额5604.76万元人民币。消息面上，公司研发的重组肺炎球菌蛋白疫苗(PBPV)于I期临床试验中获得了积极的初步结果。结果表明，PBPV在成人及老年人群中具有良好的安全性，未观察到3级不良反应和特殊的安全性风险。公司将基于I期临床试验中获得的初步结果，进行下一阶段PBPV研发工作的评估和规划。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/MzBjNmFjYTg0ZGViYjVhMGFmODhkMDhhN2E5MzY4MTQyOTQ2MzQ2MjU=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MzBjNmFjYTg0ZGViYjVhMGFmODhkMDhhN2E5MzY4MTQyOTQ2MzQ2MjU=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1935486","is_publish_highlight":false,"gpt_icon":0},{"id":"2429491960","title":"康希诺生物盘中异动 早盘股价大涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429491960","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429491960?lang=zh_cn&edition=full","pubTime":"2024-04-22 11:03","pubTimestamp":1713755003,"startTime":"0","endTime":"0","summary":"2024年04月22日早盘11时03分，康希诺生物股票出现异动，股价快速拉升5.09%。康希诺生物股票所在的生物技术行业中，整体涨幅为0.64%。消息层面，截至11时03分，康希诺生物股票正面舆情新闻比例45.45%。康希诺生物的重组肺炎球菌蛋白疫苗在I期临床试验中取得的积极结果，为该疫苗的进一步研发和应用奠定了坚实基础。未来，康希诺生物将继续携手各方伙伴，致力于推动疫苗研发领域的创新发展，为全球公共卫生事业作出更大贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221103247a54637f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221103247a54637f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429624529","title":"港股异动 | 康希诺生物(06185)涨近5% 重组肺炎球菌蛋白疫苗获得I期临床积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2429624529","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429624529?lang=zh_cn&edition=full","pubTime":"2024-04-22 10:23","pubTimestamp":1713752586,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康希诺生物涨近5%，截止发稿涨4.97%，报17.32港元，成交额721万港元。消息面上，公司昨日发布公告，公司研发的重组肺炎球菌蛋白疫苗于I期临床试验中获得了积极的初步结果。中信建投表示，2023年康希诺生物利润端受新冠疫苗收入大幅下降、退货冲减、冗余产能计入营业成本及资产减值等因素影响，表观亏损有所扩大，预计24年该部分影响有望大幅减少，叠加收入增长与费用规模控制，总体亏损有望大幅缩窄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1106300.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429196833","title":"康希诺生物：重组肺炎球菌蛋白疫苗获得I期临床积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2429196833","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2429196833?lang=zh_cn&edition=full","pubTime":"2024-04-22 08:11","pubTimestamp":1713744718,"startTime":"0","endTime":"0","summary":"康希诺生物发布公告，公司研发的重组肺炎球菌蛋白疫苗于I期临床试验中获得了积极的初步结果。在高覆盖率保护下，可以有效防止“血清型替代”的产生。同时本产品相较多糖疫苗和结合疫苗，生产工艺更为简便，易于放大和质量控制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-22/doc-inassfic1234153.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-22/doc-inassfic1234153.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429938062","title":"康希诺生物(06185.HK)PBPV临床试验取得积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2429938062","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2429938062?lang=zh_cn&edition=full","pubTime":"2024-04-21 19:59","pubTimestamp":1713700740,"startTime":"0","endTime":"0","summary":"康希诺生物(06185.HK) 公布，公司研发的重组肺炎球菌蛋白疫苗(PBPV)于I期临床试验中获得了积极的初步结果。结果表明，PBPV在成人及老年人群中具有良好的安全性，未观察到3级不良反应和特殊的安全性风险。公司将基于I期临床试验中获得的初步结果，进行下一阶段PBPV研发工作的评估和规划。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-19 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20231101162205339_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20231101162205339_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1343753/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2429938441","title":"I期临床试验成功！康希诺生物重组肺炎球菌蛋白疫苗研发取得积极成果，为全球疫苗市场带来新希望","url":"https://stock-news.laohu8.com/highlight/detail?id=2429938441","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2429938441?lang=zh_cn&edition=full","pubTime":"2024-04-21 19:40","pubTimestamp":1713699604,"startTime":"0","endTime":"0","summary":"康希诺生物的重组肺炎球菌蛋白疫苗在I期临床试验中取得的积极结果，为该疫苗的进一步研发和应用奠定了坚实基础。此次重组肺炎球菌蛋白疫苗的研发，是康希诺生物在生物医药领域技术积累和创新能力的重要体现。未来，康希诺生物将继续携手各方伙伴，致力于推动疫苗研发领域的创新发展，为全球公共卫生事业作出更大贡献。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404211940088b41e0b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404211940088b41e0b7&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cansinotech.com","stockEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.133},{"period":"3month","weight":0},{"period":"6month","weight":-0.2475},{"period":"1year","weight":-0.5197},{"period":"ytd","weight":-0.2331}],"compareEarnings":[{"period":"1week","weight":0.0584},{"period":"1month","weight":0.0442},{"period":"3month","weight":0.061},{"period":"6month","weight":-0.0113},{"period":"1year","weight":-0.1232},{"period":"ytd","weight":0.009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康希诺生物股份公司是一家处于临床阶段的中国疫苗公司。该公司的产品包括埃博拉病毒疫苗Ad5-EBOV、脑膜炎球菌疫苗MCV2和MCV4、肺炎球菌疫苗PBPV和重组新型冠状病毒疫苗等。其产品主要应用于脑膜炎、百白破和肺炎领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.023945},{"month":2,"riseRate":0.8,"avgChangeRate":0.176312},{"month":3,"riseRate":0.2,"avgChangeRate":-0.039813},{"month":4,"riseRate":0.666667,"avgChangeRate":0.07488},{"month":5,"riseRate":0.2,"avgChangeRate":-0.084834},{"month":6,"riseRate":0.6,"avgChangeRate":0.056507},{"month":7,"riseRate":0.6,"avgChangeRate":0.025366},{"month":8,"riseRate":0,"avgChangeRate":-0.212187},{"month":9,"riseRate":0.6,"avgChangeRate":-0.019121},{"month":10,"riseRate":0.6,"avgChangeRate":0.097338},{"month":11,"riseRate":0.8,"avgChangeRate":0.15426},{"month":12,"riseRate":0.6,"avgChangeRate":-0.050745}],"exchange":"SEHK","name":"康希诺生物","nameEN":"CANSINOBIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺生物,06185,康希诺生物股票,康希诺生物股票老虎,康希诺生物股票老虎国际,康希诺生物行情,康希诺生物股票行情,康希诺生物股价,康希诺生物股市,康希诺生物股票价格,康希诺生物股票交易,康希诺生物股票购买,康希诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺生物(06185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺生物(06185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}